Published in Curr Opin Nephrol Hypertens on September 01, 2016
Human mesenchymal stromal cell-derived extracellular vesicles alleviate renal ischemic reperfusion injury and enhance angiogenesis in rats. Am J Transl Res (2016) 0.78
The ZDSD rat: a novel model of diabetic nephropathy. Am J Transl Res (2017) 0.75
VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol (2006) 12.09
Incidence and mortality of acute renal failure in Medicare beneficiaries, 1992 to 2001. J Am Soc Nephrol (2006) 6.86
Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis (2009) 6.54
Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest (2003) 6.44
Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol (2007) 3.08
VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer (2008) 3.02
Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol (1998) 2.71
Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. J Am Soc Nephrol (2010) 2.52
The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int (2004) 2.42
Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol (2013) 2.28
Functional evidence that vascular endothelial growth factor may act as an autocrine factor on human podocytes. Am J Physiol Renal Physiol (2003) 2.00
Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol (2001) 1.90
Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy. Kidney Int (2000) 1.72
Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization. Oncogene (1999) 1.71
Simvastatin promotes angiogenesis and prevents microvascular remodeling in chronic renal ischemia. FASEB J (2006) 1.69
Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. J Biol Chem (2009) 1.68
Impaired endothelial proliferation and mesenchymal transition contribute to vascular rarefaction following acute kidney injury. Am J Physiol Renal Physiol (2010) 1.68
Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am J Physiol (1995) 1.60
Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties. J Am Soc Nephrol (2004) 1.59
Nephrin is critical for the action of insulin on human glomerular podocytes. Diabetes (2007) 1.55
Renal ischemia reperfusion inhibits VEGF expression and induces ADAMTS-1, a novel VEGF inhibitor. Am J Physiol Renal Physiol (2008) 1.46
VEGF-121 preserves renal microvessel structure and ameliorates secondary renal disease following acute kidney injury. Am J Physiol Renal Physiol (2008) 1.41
Human mesangial cells and peripheral blood mononuclear cells produce vascular permeability factor. Kidney Int (1993) 1.40
Vascular endothelial growth factor (VEGF121) protects rats from renal infarction in thrombotic microangiopathy. Kidney Int (2001) 1.40
Vascular Endothelial Growth Factor and Podocyte Protection in Chronic Hypoxia: Effects of Endothelin-A Receptor Antagonism. Am J Nephrol (2016) 1.40
Autocrine VEGF-A system in podocytes regulates podocin and its interaction with CD2AP. Am J Physiol Renal Physiol (2006) 1.38
Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease. Kidney Int (2010) 1.38
Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothelial damage/dysfunction and atherosclerosis. Atherosclerosis (2004) 1.28
Post-cyclosporine-mediated hypertension and nephropathy: amelioration by vascular endothelial growth factor. Am J Physiol Renal Physiol (2001) 1.27
Receptors of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in fetal and adult human kidney: localization and [125I]VEGF binding sites. J Am Soc Nephrol (1998) 1.22
Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease. Am J Physiol Renal Physiol (2007) 1.17
Vegfa protects the glomerular microvasculature in diabetes. Diabetes (2012) 1.16
Podocyte vascular endothelial growth factor (Vegf₁₆₄) overexpression causes severe nodular glomerulosclerosis in a mouse model of type 1 diabetes. Diabetologia (2011) 1.15
Reversal of renal dysfunction by targeted administration of VEGF into the stenotic kidney: a novel potential therapeutic approach. Am J Physiol Renal Physiol (2012) 1.13
The balance of autocrine VEGF-A and VEGF-C determines podocyte survival. Am J Physiol Renal Physiol (2009) 1.12
Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy. Kidney Int Suppl (2000) 1.07
Induction of podocyte VEGF164 overexpression at different stages of development causes congenital nephrosis or steroid-resistant nephrotic syndrome. Am J Pathol (2010) 1.07
Vascular endothelial growth factor receptor 2 direct interaction with nephrin links VEGF-A signals to actin in kidney podocytes. J Biol Chem (2011) 1.05
Detection of multiple vascular endothelial growth factor splice isoforms in single glomerular podocytes. Kidney Int Suppl (1998) 1.03
VEGF and podocytes in diabetic nephropathy. Semin Nephrol (2012) 1.02
VEGF-induced mobilization of caveolae and increase in permeability of endothelial cells. Am J Physiol Cell Physiol (2002) 1.01
Structural mechanisms of acute VEGF effect on microvessel permeability. Am J Physiol Heart Circ Physiol (2003) 1.00
Openings through endothelial cells associated with increased microvascular permeability. Microcirculation (1999) 1.00
Diabetic nephropathy: Is it time yet for routine kidney biopsy? World J Diabetes (2013) 0.98
Vascular endothelial growth factor receptors in human mesangium in vitro and in glomerular disease. J Am Soc Nephrol (2000) 0.95
Role of angiotensin II in the development of nephropathy and podocytopathy of diabetes. Curr Diabetes Rev (2011) 0.94
Endothelial-podocyte crosstalk: the missing link between endothelial dysfunction and albuminuria in diabetes. Diabetes (2013) 0.93
Insulin directly stimulates VEGF-A production in the glomerular podocyte. Am J Physiol Renal Physiol (2013) 0.93
Vascular Endothelial Growth Factor-A165b Is Protective and Restores Endothelial Glycocalyx in Diabetic Nephropathy. J Am Soc Nephrol (2014) 0.92
Nox-4 deletion reduces oxidative stress and injury by PKC-α-associated mechanisms in diabetic nephropathy. Physiol Rep (2014) 0.90
Vascular endothelial growth factor administration does not improve microvascular disease in the salt-dependent phase of post-angiotensin II hypertension. Am J Physiol Renal Physiol (2006) 0.87
Podocytes, signaling pathways, and vascular factors in diabetic kidney disease. Adv Chronic Kidney Dis (2014) 0.86
Hemodialysis in diabetic patients. Am J Kidney Dis (2001) 0.84
Podocyte-specific Nox4 deletion affords renoprotection in a mouse model of diabetic nephropathy. Diabetologia (2015) 0.84
Renal Therapeutic Angiogenesis Using a Bioengineered Polymer-Stabilized Vascular Endothelial Growth Factor Construct. J Am Soc Nephrol (2015) 0.83
Growth factor purification and delivery systems (PADS) for therapeutic angiogenesis. Vasc Cell (2015) 0.82
Sulodexide improves renal function through reduction of vascular endothelial growth factor in type 2 diabetic rats. Life Sci (2013) 0.82
Collapsing glomerulopathy superimposed on diabetic nephropathy: insights into etiology of an under-recognized, severe pattern of glomerular injury. Nephrol Dial Transplant (2013) 0.80
Sugar, sex, and TGF-β in diabetic nephropathy. Semin Nephrol (2012) 0.80
Characterization and kinetic mechanism of catalytic domain of human vascular endothelial growth factor receptor-2 tyrosine kinase (VEGFR2 TK), a key enzyme in angiogenesis. Biochemistry (1998) 0.80
Vascular endothelial growth factor and the kidney: something of the marvellous. Curr Opin Nephrol Hypertens (2014) 0.79
Protective effects of adiponectin on uncoupling of glomerular VEGF-NO axis in early streptozotocin-induced type 2 diabetic rats. Int Urol Nephrol (2014) 0.79
Vascular endothelial growth factors: multitasking functionality in metabolism, health and disease. J Inherit Metab Dis (2015) 0.78
Progesterone ameliorates diabetic nephropathy in streptozotocin-induced diabetic Rats. Diabetol Metab Syndr (2015) 0.77
The role of vascular endothelial growth factor in the kidney in health and disease. Nephron Physiol (2004) 0.77
Recent advances in the understanding of the pathophysiology of preeclampsia. Hypertension (2013) 1.71
Evaluation of cell penetrating peptides fused to elastin-like polypeptide for drug delivery. J Control Release (2005) 1.32
Cajal-body formation correlates with differential coilin phosphorylation in primary and transformed cell lines. J Cell Sci (2009) 1.16
Therapeutic peptides for cancer therapy. Part II - cell cycle inhibitory peptides and apoptosis-inducing peptides. Expert Opin Drug Deliv (2009) 1.05
Inhibition of ovarian cancer cell proliferation by a cell cycle inhibitory peptide fused to a thermally responsive polypeptide carrier. Int J Cancer (2010) 0.98
Slow assembly and disassembly of lambda Cro repressor dimers. J Mol Biol (2005) 0.88
Renal medullary endothelin-1 is decreased in Dahl salt-sensitive rats. Am J Physiol Regul Integr Comp Physiol (2011) 0.88
A polypeptide drug carrier for maternal delivery and prevention of fetal exposure. J Drug Target (2014) 0.87
Thermally targeted delivery of chemotherapeutics and anti-cancer peptides by elastin-like polypeptide. Expert Opin Drug Deliv (2008) 0.86
Inhibition of ovarian cancer cell metastasis by a fusion polypeptide Tat-ELP. Clin Exp Metastasis (2009) 0.85
Role of 20-hydroxyeicosatetraenoic acid in mediating hypertension in response to chronic renal medullary endothelin type B receptor blockade. PLoS One (2011) 0.85
Placental ischemia impairs middle cerebral artery myogenic responses in the pregnant rat. Hypertension (2011) 0.83
[The heart during pregnancy]. Rev Esp Cardiol (2011) 0.83
Structural and hydrodynamic analysis of a novel drug delivery vector: ELP[V5G3A2-150]. Biophys J (2013) 0.78
Heme oxygenase-1 promotes migration and β-epithelial Na+ channel expression in cytotrophoblasts and ischemic placentas. Am J Physiol Regul Integr Comp Physiol (2014) 0.77
Effect of basic cell-penetrating peptides on the structural, thermodynamic, and hydrodynamic properties of a novel drug delivery vector, ELP[V5G3A2-150]. Biochemistry (2014) 0.76
Nitroreductase-triggered activation of a novel caged fluorescent probe obtained from methylene blue. Chem Commun (Camb) (2015) 0.76
STOX1: a new player in preeclampsia? Hypertension (2013) 0.75
Safety and Pharmacokinetics of Intranasally Administered Heparin. medRxiv (2022) 0.75